Peregrine found dead amid new case of bird flu
The female bird of prey was found at the Priory having only laid eggs in the nest three weeks earlier.
The Priory said: 'Sad news today - we're very sorry to have to let you know that our female peregrine has died.
'Members of the Priory staff team are in touch with the appropriate authorities.
'To anticipate the questions, nothing is known at present,' and added any information will be shared once known.
Dorset Police said it is not investigating the death. It's not known whether bird flu is what caused the death of the peregrine.
Meanwhile, it's understood two swans and a cygnet were also found dead in Mudeford last week.
A BCP Council spokesman said: 'We are aware of a recent confirmed case of avian flu in a dead wild bird found in the BCP area.
'The risk of avian flu passing from infected dead birds to humans is low.
'Residents are advised not to touch dead wild birds and to report any dead wild birds to the DEFRA helpline on 03459 33 55 77 or by visiting https://www.gov.uk/guidance/report-dead-wild-birds .'
Residents should let the Defra helpline know if they find a single bird of prey, including owls, or three or more dead wild waterfowl (swans, geese or ducks) or gulls.
They should also contact Defra if five or more dead birds of any other species are spotted.
Defra remains tight-lipped about whether bird flu has been noted in the area, saying it is unable to comment on any testing or reports of bird flu.
The Animal and Plant Health Agency, part of Defra, carries out year-round surveillance of dead wild birds submitted via public reports and warden patrols as part of its wild bird surveillance programme.
The RSPCA has not had any reports of dead swans or peregrines in Christchurch. The RSPB has been approached for a comment but did not respond.
Last month, a confirmed case of bird flu was found at Longham Lakes.
Bird flu, also known as avian flu is a virus that has been around for a number of years in the UK.
It is an infectious type of influenza that spreads among birds and in rare cases, it can affect humans.
There are many different types of bird flu viruses and many of them don't infect humans. However, there are four strains that have caused concern in recent years.
The NHS says although H5N1, H7N9 and H5N6 don't easily infect people and aren't usually spread by human contact, there have been several people infected around the world, resulting in a number of deaths.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses by either single or two-dose intranasal (IN) or intramuscular (IM) administration in nonhuman primates. Results were published in Nature Communications. "These preclinical results underscore the promise and potential of our pandemic influenza program as well as the strength of our technology platform and our ability to deliver against our corporate growth strategy," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President and Head of Research and Development, Novavax. "Our R&D pipeline focuses on delivering assets ready for partnership and prioritizing areas of unmet medical need, including vaccines for avian pandemic influenza, where we see clear potential advantages for our technology compared with other vaccines that are licensed or in development." Results showed that a single dose administered by either IN or IM routes induced neutralizing antibody responses (IN: 1:54; IM: 1:1,160), at or above the 1:40 titer generally considered to be a protective antibody response. The data showed even higher levels of immunity after two doses. These data suggest that even a single IN dose has the potential to provide protective immunity in individuals previously exposed to seasonal influenza either by vaccination or infection. Further, data showed Novavax's H5N1 vaccine candidate elicited broad antibody responses, suggesting the potential to protect against forward-drift variants from currently circulating strains of the H5N1 virus. H5N1, a highly pathogenic and dynamic avian pandemic influenza virus, is of concern due to its potential to mutate into a strain adapted for sustained human-to-human transmission. To date, there have been 70 confirmed total reported human cases in the U.S., and one death associated with H5N1 avian pandemic influenza infection.1 As of July 2025, no reported cases in the U.S. have been proven to result from human-to-human transmission. As part of its corporate growth strategy, Novavax is making targeted investments in early-stage development programs to create value. Novavax intends to pursue funding, partnership and licensing opportunities for its H5N1 vaccine candidate. About Novavax Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development (R&D) innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit and LinkedIn for more information. Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, and the potential for a single intranasal or intramuscular dose differentiating Novavax's H5N1 vaccine, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for its product candidates; challenges or delays in obtaining regulatory authorization for its product candidates, including for future COVID-19 variant strain changes, its CIC vaccine candidate, its stand-alone influenza vaccine candidate or other product candidates; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Novavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners; challenges in implementing its global restructuring and cost reduction plan; challenges in obtaining commercial adoption and market acceptance of its updated COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidate and stand-alone influenza vaccine candidate or other product candidates; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19 or influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: Investors Luis Sanay, CFA 240-268-2022 ir@ Media Giovanna Chandler (844) 264-8571 media@ References U.S. Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. 2025. Available at: View original content to download multimedia: SOURCE Novavax, Inc.


Hamilton Spectator
5 hours ago
- Hamilton Spectator
Microbix Exhibiting & Presenting at ADLM
MISSISSAUGA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending, exhibiting, and presenting at the Association for Diagnostic & Laboratory Medicine ('ADLM') conference taking place in Chicago, Illinois July 28 to 31, 2025. At ADLM, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of many infectious and other diseases. Microbix will thereby showcase its ever-growing portfolio of quality assessment products ('QAPs™') that help ensure the accuracy of antigen and molecular (i.e., 'PCR' or 'NAAT') tests and their workflows. Microbix will also be meeting with many current and prospective clients to determine how best to support their quality management system needs. Also at ADLM, Microbix will present results of a pilot External Quality Assessment (EQA) program enabled by Microbix QAPs. Its poster is titled 'Quality Control Rapid Response in Pre-Pandemic Preparedness Showcasing a Synthetic H5N1 Genetic Template.' which reviews the performance of novel QAPs for answering the critical question of whether pre-existing molecular tests for Influenza A can accurately detect the emerging H5N1 (Bird Flu) pandemic strain. A Microbix customer and collaborator, American Proficiency Institute ('API'), is presenting a related poster titled 'Evaluation of NAAT Recovery of Highly Pathogenic Avian Influenza A (H5N1) Clade 2.3.4.4b from Novel Proficiency Samples.' After each poster is presented at ADLM, they will be made available at . The two posters detail the results of work first announced on January 13, 2025, whereby Microbix and API disclosed the creation of QAPs and a pilot proficiency testing program for evaluating the performance of Flu tests in detecting H5N1. As widely reported in the media, H5N1 Flu is a novel variant for which the human population does not have established immunity. Accordingly, H5N1 Flu has pandemic potential, with it having thus far caused severe disease or death in approximately 50% of those persons infected. Microbix gratefully acknowledges the vital role of API in helping to conduct this societally important work. Amer Alagic, Microbix's Director of R&D and lead author of its poster commented, 'Working alongside API, our team is privileged to help answer vital questions concerning the accuracy and usefulness of currently available Flu tests for detecting H5N1. Microbix's novel H5N1 QAPs were created by our team to ensure full genetic coverage of a potential pandemic strain and were made safely under Microbix IP and with cutting-edge synthetic biology techniques. H5N1 QAPs are fully-characterized, accurately-quantified, and are available in liquid and FLOQSwab formats to support both lab-based and point-of-care assays. These Microbix capabilities can be rapidly deployed in response to any emerging pandemic.' Purchase enquiries for these or other Microbix QAPs can be e-mailed to . About Microbix Biosystems Inc. Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues targeting C$ 2.0 million or more per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency-testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Forward-Looking Information This news release includes 'forward-looking information,' as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of API, the pilot proficiency testing program, the H5N1 QAPs, or their relevance, Microbix's or others' products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, access and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and actual performance may be affected by many material factors, some of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix's judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information. Please visit or for recent Microbix news and filings. For further information, please contact Microbix at: Copyright © 2025 Microbix Biosystems Inc. Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix Biosystems Inc. FLOQ® and FLOQSwab® are trademarks of Copan Italia S.p.A. Other companies' names and products are protected by their respective trademarks.
Yahoo
4 days ago
- Yahoo
'Significant health risks' as laughing gas on the rise at Dorset beaches
PEOPLE using balloons filled with laughing gas is on the rise, according to Dorset Police, despite possession now being illegal. Nitrous oxide - also known as laughing gas and commonly consumed using balloons, however due to serious health concerns, it has been reclassified as a Class C drug. A spokesperson for Dorset Police said: 'Nationally, we have seen a stark increase in the use of NOS during 2025. 'Be under no illusion - there are significant health risks associated with use of this drug. Earlier this week one of our neighbourhood inspectors spoke to an anaesthetist doctor at Bournemouth Hospital around NOS, primarily to discuss risks to our officers in dealing with it.' The doctor informed police that when the substance is used outside a medical environment, it can cause issues with fertility, vitamin B12 deficiency (leading to nerve damage, and problems with DNA synthesis. Regular use prevents the body producing white blood cells. It also contributes to greenhouse gases and appropriate disposal of NOS cannisters comes at an avoidable cost to local authorities. The police spokesperson added: 'People are undertaking this behaviour at the beaches. "If you observe this behaviour, approach and discreetly inform a member of BCP Council beach front staff (pink polo shirts) or an RNLI lifeguard. "They will notify the Police who are deployed on foot at the beach. Similarly if you sight a police officer, please approach and advise them direct.'